Develops peptide-based drug candidates for inflammatory diseases, blood disorders and obesity, and licenses some candidates to pharmaceutical partners.
10-K for FY2025, filed Feb 25, 2026Protagonist Therapeutics, Inc. (referred to as “Protagonist,” the “Company,” “we,” “our” or “us”) is an integrated discovery and…View ↗
Icotyde™ (icotrokinra) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor…View ↗
RusfertideView ↗
PN-881. We are developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin…View ↗
PN-477. In June 2025, we nominated PN-477, a potential best-in-class novel triple GLP-1, GIP and GCG receptor agonist peptide with oral…View ↗
Pharmaceutical partners pay upfront and milestone amounts and share costs under collaboration agreements; Protagonist also earns royalties on licensed products’ sales. License income is earned when a partner can use the rights, while royalties follow product sales.
10-K for FY2025, filed Feb 25, 2026The Company derives revenues from its collaboration partners, consisting of non-refundable upfront and milestone payments and cost sharing…View ↗
Licenses of intellectual property: If a license to the Company’s intellectual property is determined to be distinct from the other…View ↗
Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, where the license…View ↗
$46M
10-K for FY2025, filed Feb 25, 2026
$46M ↗
Pharmaceutical partners JNJ and Takeda contract with Protagonist under license and collaboration agreements; revenue includes their upfront and milestone payments and cost-sharing payments.
10-K for FY2025, filed Feb 25, 2026The Company derives revenues from its collaboration partners, consisting of non-refundable upfront and milestone payments and cost sharing…View ↗
We and JNJ are parties to a license and collaboration agreement related to the development and commercialization of Icotyde. We entered…View ↗
In January 2024, we entered into a worldwide license and collaboration agreement for rusfertide with Takeda (the “Takeda Collaboration…View ↗
10-K for FY2025, filed Feb 25, 2026
The Company derives revenues from its collaboration partners, consisting of non-refundable upfront and milestone payments and cost sharing…View ↗
Not on paper. It lost $130.1M in FY2025, but brought in more cash than it spent: $56.1M of free cash flow.
10-Q for Q3 FY2026, filed Nov 6, 2026
$220MView ↗
8-K, filed Aug 5, 2026
Takeda holds exclusive worldwide development and commercialization rights to rusfertide following Protagonist's opt-out election in April…View ↗
Growing. Revenue grew 68% in 4 years, from $27.4M in FY2021 to $46M in FY2025, about 14% a year.
Broader disease focus
The older report describes hematology and inflammatory programs; the latest also describes obesity candidates, including peptide agonists in oral and injectable forms.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Feb 25, 2026We are a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly known as PN-235) in different…View ↗
Protagonist Therapeutics, Inc. (referred to as “Protagonist,” the “Company,” “we,” “our” or “us”) is an integrated discovery and…View ↗
PN-477. In June 2025, we nominated PN-477, a potential best-in-class novel triple GLP-1, GIP and GCG receptor agonist peptide with oral…View ↗
PN-458. In December 2025, we nominated development candidate PN-458, a potential best-in-class novel dual GLP-1 and GIP receptor agonist…View ↗
Rusfertide partnership
The older report describes rusfertide as wholly owned; the latest describes a co-development and co-commercialization arrangement with Takeda.
10-K for FY2022, filed Mar 15, 2023Our most advanced clinical asset, rusfertide (generic name for PTG-300), is an injectable hepcidin mimetic in development for the potential…View ↗
Competes with Novartis, Eli Lilly, Bausch Health, Johnson & Johnson, AbbVie, UCB, Amgen, Pfizer, Bristol Myers Squibb, Takeda, Alumis, Gilead, Incyte, Italfarmaco, Silence Therapeutics, Disc Medicine, Novo Nordisk, Viking Therapeutics, Structure Therapeutics, and Boehringer Ingelheim
10-K for FY2025, filed Feb 25, 2026In psoriasis and PsA, competition will come from companies with approved injectable agents in the IL-17 and IL-12/23 pathway, including…View ↗
Loading...